Received Feb 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 2 | — | — |
COVID; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. Previously administered products included for Product used for unknown indication: Influenza vaccine (got flu vaccine in the fall.). Past adverse reactions to the above products included No adverse effect with Influenza vaccine. In 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 20-May-2023, the patient experienced COVID-19 (COVID). At the time of the report, COVID-19 (COVID) outcome was unknown. Concomitant medication was not provided. It was reported that the patient had completed the two dose primary Moderna series in 2021. She noted that she contracted COVID 19 in 20-May, may and Jun-2023 and therefore did not receive any COVID 19 vaccines after 2021 until the recent dose in feb-2026. It was unknown if the patient experienced any additional symptoms or events. Treatment medication was not reported. This case was linked to MOD-2026-794000 (Patient Link).